Importantly, these studies focused solely on TGF-β1 SNPs and we were therefore unable to investigate the contribution of TGF-β2 or TGF-β3 polymorphisms to the development of end-stage CHD. This evidence concerns the gene TGFB1 and coronary artery disorder.